Table 3.

Clinical trials for multiple myeloma, based on https://clinicaltrials.gov/, as of March 13, 2015. ASCT: autologous stem cell transplantation; PD-L-1: programmed death-1 ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; IGF-1R: insulin growth factor-1 receptor; KIR: killer cell Ig-like receptor; DKK: Dickkopf-related protein; BTK: Bruton's tyrosine kinase; PI3k: phosphoinositide 3-kinase; PARP: poly(ADP-ribose) polymerase.

Multiple myeloma  1908 studies	Monoclonal antibodies  82 studies	Anti-CD38	4 studies	Phase 2
		Anti-IL6 siltuximab	5 studies	Combination
		Anti-CD40	4 studies	Phase 1/2
		Anti-transferrin R	1 study	Phase 1/2
		Anti-GM2	1 study	Phase 1/2
		Anti-CD66 90Y	1 study	+ ASCT
		Anti-CD45 90Y	1 study	+ allogeneic transplantation
		Anti-Adhesion Mol1	1 study	Phase 1
		Anti-CD38	1 study	Combination
		Anti-PDL1	3 studies	Phase 2 with vaccination
				Combination with lenalidomide
		Anti-IGF1R	1 study	Phase 1
		Bevacizumab	3 studies	Phase 2 combination
		Anti-KIR	4 studies	Phase 1 and Phase 2
		Anti-CTLA-4	2 studies	+ allogeneic T.
		Anti-CD52	3 studies	+ allogeneic T.
		Anti-DKK1	1 study	Randomized Phase 2
		Anti-CD20	90Y/131I 2 studies	+ ASCT
			Cold: 3 studies	Combination
		Anti-CD56	1 study	Phase I
		Elotuzumab	5 studies	Randomized Phase 1/2
		Anti-GRP78 (PAT-SM6)	1 study	Phase 1
		Anti-CXCR4	1 study	Phase 1b
	BTK inhibitors	Ibrutinib  ACP-196/ACP-319	2 studies (+ carfilzomib)  3 studies	Phase 2  Phase 1b
	PI3 kinase inhibitors	Idelalisib, BYL719, CUDC-907, nelfinavir, SOM230 LAR, and sorafenib		Phase 1/2
	Anti-CDK	Dinaciclib	Combination	Phase 1/2
	Antiproteasome	Carfilzomib  Ixazomib  Oprozomib   Marizomib	10 studies	Phase 3      Phase 1
	HDAC	Ricolinostat,  vorinostat	Combination	Phase 1b
	PARP inhibitor	ABT-888	Combination	Phase 1